

# Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis

M.L. Ou<sup>1,2\*</sup>, G. Liu<sup>4\*</sup>, D. Xiao<sup>1</sup>, B.H. Zhang<sup>1</sup>, C.C. Guo<sup>1</sup>, X.G. Ye<sup>1</sup>, Y. Liu<sup>1</sup>, N. Zhang<sup>1</sup>, M. Wang<sup>1</sup>, Y.J. Han<sup>1</sup>, X.H. Ye<sup>1</sup>, C.X. Jing<sup>1,3</sup> and G. Yang<sup>2,3</sup>

<sup>1</sup>Department of Epidemiology, School of Medicine, Jinan University, Guangzhou, Guangdong, China
<sup>2</sup>Department of Parasitology, School of Medicine, Jinan University, Guangzhou, Guangdong, China
<sup>3</sup>Key Laboratory of Environmental Exposure and Health in Guangzhou, Jinan University, Guangzhou, Guangdong, China
<sup>4</sup>Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong, China

\*These authors contributed equally to this study. Corresponding authors: G. Yang / C.X. Jing E-mail: guangyangph@gmail.com / jcxphd@gmail.com

Genet. Mol. Res. 15 (3): gmr.15038703 Received April 8, 2016 Accepted June 7, 2016 Published September 16, 2016 DOI http://dx.doi.org/10.4238/gmr.15038703

Copyright © 2016 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-SA) 4.0 License.

**ABSTRACT.** miR-137, a brain-enriched microRNA, is involved in the control of neuronal proliferation, differentiation, and dendritic arborization, all of which are important for proper neurogenesis and relevant to schizophrenia. miR-137 is also known to regulate many genes implicated in schizophrenia risk. Although reports have associated the miR-137 polymorphism rs1625579 with this disease, their results have been inconsistent. The aim of this meta-analysis was to evaluate the relationship between rs1625579 and schizophrenia. Data were obtained from an electronic database, and pooled odds ratios (ORs) with 95%

Genetics and Molecular Research 15 (3): gmr.15038703

confidence intervals (95%CI) were used to test the association using the RevMan 5.3 software. Twelve case-control studies comprising 11,583 cases and 14,315 controls were included. An estimated lambda value of 0.46 was recorded, suggesting that a codominant model of inheritance was most likely. A statistically significant association was established under allelic (T *vs* G: OR = 1.15, 95%CI = 1.10-1.21, P < 0.001) and homogeneous codominant models (TT *vs* GG: OR = 1.32, 95%CI = 1.13-1.54, P < 0.001), but no such relationship was detected using the heterogeneous codominant model (GT *vs* GG: OR = 1.14, 95%CI = 0.97-1.34, P=0.11). This meta-analysis demonstrates that the rs1625579 miR-137 genetic variant significantly increases schizophrenia risk.

**Key words:** Schizophrenia; miR-137; Single nucleotide polymorphism; Meta-analysis; Fixed-effect analysis

# **INTRODUCTION**

Schizophrenia is a severe, chronic psychiatric disorder arising in late adolescence that profoundly affects neural development and disrupts key traits such as cognition and personality (van Os and Kapur, 2009). The median incidence of this disease is reported to be 15.2 per 100,000 people (McGrath et al., 2008), and its median lifetime prevalence is estimated at 480 per 100,000 patients (Simeone et al., 2015). Moreover, schizophrenia is a major cause of disability (Warner, 2009), with approximately three-quarters of patients suffering an ongoing disability with relapses (Smith et al., 2010).

Schizophrenia is a multifactorial disorder. Although its etiology is unclear, it is widely acknowledged that the development of this disease derives from a combination of genetic and environmental factors (O'Donovan et al., 2003). Some studies have shown that single nucleotide polymorphisms (SNPs) in several genes, such as those encoding vaccinia-related kinase 2 (Zhang et al., 2015), dopamine D2 receptor (Liu et al., 2012), and regulator of G-protein signaling 9 (Zhu et al., 2015) may play major roles in the development of schizophrenia. In addition, the clinical symptoms of schizophrenia are complicated, involving perception, thought, emotion, action, cognitive function, and other faculties. These vary greatly between patients, and even the same individual may exhibit different symptoms at various stages. Analysis of the psychopathological features of various psychotic disorders suggests that symptoms can be clustered into five main categories (van Os and Kapur, 2009). Therefore, if a meaningful molecular marker for schizophrenia screening can be established, at-risk carriers may be identified and corresponding early interventions provided, potentially improving prognosis.

To date, many studies have described the involvement of microRNAs (miRNAs) in nervous system regulation, including neuronal migration and differentiation, synaptic plasticity, and adult neurogenesis (Kosik, 2006). SNPs in genes encoding miRNAs such as miR-206 (rs17578796; Hansen et al., 2007) and miR-30e (rs112439044; Xu et al., 2010) may affect the properties of the transcribed sequences by altering their expression and/or maturation (Saunders et al., 2007), resulting in nervous system disorders such as schizophrenia (Hommers et al., 2015). Notably, the largest schizophrenia genome-wide association study (GWAS) carried out to date found the SNP rs1625579 (G>T), located within an intron of the miR-137 primary transcript, to be associated with this disease (Ripke et al., 2011). Lett et al.

Genetics and Molecular Research 15 (3): gmr.15038703

(2013) also reported that North American schizophrenia patients carrying the TT genotype of this variant have reduced brain white matter density, diminished hippocampal volume, and increased lateral ventricle volume. However, other studies have not supported an association between miR-137 rs1625579 and schizophrenia or white matter microstructure (Kelly et al., 2014; Rose et al., 2014; Wang et al., 2014). Therefore, no consistent conclusion has been reached regarding the effect of this SNP on schizophrenia. The purpose of this meta-analysis was to explore the relationship between miR-137 rs1625579 and this condition.

## **MATERIAL AND METHODS**

#### **Identification of eligible studies**

A search of the PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Science Direct, Wiley Online Library, Chinese National Knowledge Infrastructure, and Wanfang Data Resource databases was conducted during August 2015 using the search terms ("miR-137" or "rs1625579") and ("Schizophrenia"), with no limitations placed on language. All references included in the relevant studies were extensively examined for additional publications.

## Inclusion and exclusion criteria

To be included in the present meta-analysis, studies had to: a) evaluate the miR-137 rs1625579 polymorphism in relation to schizophrenia; b) consist of a human case-control study; c) include patients meeting the diagnostic criteria for schizophrenia; as well as d) report detailed genotype data for the calculation of odds ratios (ORs) and 95% confidence intervals (CIs). The following were excluded from the current analysis: i) studies not based on a case-control design; ii) duplicates of previous publications; iii) abstracts, comments, reviews, posters, and editorials; and iv) reports lacking detailed genotype data. Where multiple investigations used overlapping data, the latest study was included.

# **Data extraction**

Data for this meta-analysis were extracted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with slight modifications. Three investigators (M.L. Ou, D. Xiao, and B.H. Zhang) independently extracted the following data from eligible studies: first author, year of publication, country of origin, ethnicity, number of cases and controls, Hardy-Weinberg equilibrium (HWE) score, and allele and genotype frequencies, amongst other information. Where detailed data were lacking, we attempted to contact the corresponding author to obtain the original dataset. Studies were then excluded if the authors did not provide additional information. Any disagreement between the researchers responsible for extracting data was resolved by consensus. After extraction, the data were reviewed and compared by C.X. Jing.

# Quality assessment

All included studies were assessed according to the Newcastle-Ottawa scale (NOS) criteria (Stang, 2010), which use a "star" rating system to check methodological quality with

Genetics and Molecular Research 15 (3): gmr.15038703

regard to three aspects: selection, comparability, and exposure. Scores range from zero (low) to nine stars (high). Articles scoring <5 were classified as "low quality", and those scoring  $\geq 5$  were considered "high quality".

## **Statistical analysis**

HWE was evaluated among the control groups of each study using the chi-square test. P < 0.05 was considered to represent departure from HWE. Pooled ORs and their 95%CIs were used to assess the association between miR-137 rs1625579 and susceptibility to schizophrenia under an appropriate model using the RevMan 5.3 software (Cochrane, 2014). Pooled ORs with Z-test P values <0.05 were regarded as statistically significant. Statistical heterogeneity among studies was tested by Cochran's Q-statistic and the  $I^2$  metric (Higgins and Thompson, 2002). Values of  $I^2 > 50\%$  and P < 0.10 were considered to indicate significant heterogeneity. In the absence of heterogeneity, a fixed-effect model (using the Mantel-Haenszel method) was used; otherwise, a random-effect model (using the DerSimonian and Laird method) was employed. A Begg's funnel plot was generated to assess potential publication bias, and sensitivity analysis was performed with the Comprehensive Meta-analysis software (Biostat Inc., Englewood, NJ, USA).

# Per-allele and per-genotype analysis

In our study, the T and G variants were deemed risk and non-risk alleles, respectively. Correspondingly, the TT, GT, and GG genotypes were viewed as mutant homozygous, heterozygous, and wild-type homozygous, respectively. First, we estimated the effect of the risk allele on schizophrenia susceptibility using an allelic model (T *vs* G). Subsequently, we used the model-free Bayesian approach (Minelli et al., 2005) to estimate genotypic effects as TT *vs* GG (OR<sub>1</sub>) and GT *vs* GG (OR<sub>2</sub>). The parameter lambda ( $\lambda$ ), defined as the ratio of logOR<sub>2</sub> to logOR<sub>1</sub>, was used to gauge the genetic mode of inheritance. Lambda values range from 0 to 1:  $\lambda = 0$  suggests a recessive model (TT *vs* GT+GG);  $\lambda = 1$ , a dominant model (GT+TT *vs* GG); and if  $\lambda = 0.5$ , a codominant model (TT *vs* GG; GT *vs* GG) is implied. If  $\lambda > 1$  or < 0, then a homozygous or heterosis model is likely, although such cases are rare (Minelli et al., 2005). WinBUGS 1.4.3 (University of Cambridge, England, UK) was used with vague prior distributions for estimation of parameters (i.e.,  $\lambda$  and ORs). Models were run with a burn-in of 1000 iterations, followed by 10,000 iterations for parameter estimates.


# RESULTS

#### **Characteristics of eligible studies**

In total, 371 relevant studies were retrieved in the initial search. Following screening, 272 records were excluded, of which 66 were duplicates, 159 irrelevant to the topic, and 47 were posters, comments, or abstracts. Thus, 99 published articles were retained. A further 76 unrelated and non-human studies were excluded by reading titles and abstracts. We then assessed the full texts of the remaining 23 publications, and excluded 11 that lacked key information or case and control data, did not concern rs1625579, or consisted of duplicate data (Figure 1). Twelve case-control studies (Ripke et al., 2011; Lett et al., 2013; Green et al.,

Genetics and Molecular Research 15 (3): gmr.15038703

2013; van Erp et al., 2014; Guan et al., 2014; Rose et al., 2014; Wang et al., 2014; Ma et al., 2014; Yuan et al., 2015; Strazisar et al., 2015; Kuswanto et al., 2015; Sun et al., 2015) were therefore included in our meta-analysis, comprising 11,583 cases and 14,315 controls. Their general characteristics are listed in Table 1, and corresponding quality scores are given in Table S1. Genotype distributions among the control groups of all studies were consistent with HWE (P > 0.05).



**Figure 1.** Flowchart showing the identification of relevant studies regarding the relationship between the miR-137 polymorphism of interest and schizophrenia. GWAS = genome-wide association study.

Genetics and Molecular Research 15 (3): gmr.15038703

M.L. Ou et al.

Study	Country	Ethnicity	N	HWE		Cases			Contro	ls
			(cases/controls)	(P)	GG	GT	TT	GG	GT	TT
van Erp et al. (2014)	USA	Caucasian, Black, Asian	48/63	>0.05	0	9	39	2	15	46
Guan et al. (2014)	China	Asian	1429/1570	>0.05	21	297	1111	38	370	116
Rose et al. (2014)	Ireland	Caucasian	163/150	>0.05	2	49	112	4	41	105
Yuan et al. (2015)	China	Asian	506/520	>0.05	2	59	445	0	54	46
Lett et al. (2013)	USA, Canada	Caucasian, Non-Caucasian	510/121	>0.05	14	152	344	5	40	76
Green et al. (2013)	Australia	Caucasian	491/328	>0.05	19	153	319	14	109	20:
Strazisar et al. (2015)	Sweden	Caucasian	407/832	>0.05	21	119	267	44	275	51
Kuswanto et al. (2015)	China	Asian	84/63	>0.05	1	9	74	2	5	56
Wang et al. (2014)	China	Asian	300/300	>0.05	0	31	269	0	35	26
Ma et al. (2014)	China	Asian	611/628	>0.05	2	59	550	5	82	54
Sun et al. (2015)	China	Asian	589/622	>0.05	5	72	512	3	79	54
UK <sup>a</sup>	UK	Caucasian	472/2934	>0.05	15	137	320	109	914	191
CATIE <sup>a</sup>	USA	Caucasian	402/207	>0.05	12	115	275	7	62	13
Aberdeen <sup>a</sup>	UK	Caucasian	720/698	>0.05	21	202	497	27	222	44
Cardiffa	Bulgaria	Caucasian	527/609	>0.05	17	157	353	30	211	36
London <sup>a</sup>	UK	Caucasian	518/491	>0.05	15	145	358	19	157	31
Portugal <sup>a</sup>	Portugal	Caucasian	346/215	>0.05	7	87	252	6	60	14
Swedish1 <sup>a</sup>	Sweden	Caucasian	168/167	>0.05	6	53	109	9	60	- 98
Swedish2 <sup>a</sup>	Sweden	Caucasian	390/229	>0.05	17	128	245	13	84	132
Bonn <sup>a</sup>	Germany	Caucasian	474/1304	>0.05	20	153	301	58	434	81
Copenhagen <sup>a</sup>	Denmark	Caucasian	482/457	>0.05	18	151	313	25	164	26
Munich <sup>a</sup>	Germany	Caucasian	434/351	>0.05	16	134	284	15	116	22
TOP3 <sup>a</sup>	Norway	Caucasian	248/351	>0.05	11	83	154	15	115	22
UCLA <sup>a</sup>	Netherlands	Caucasian	704/631	>0.05	21	201	482	26	206	39
Hillside <sup>a</sup>	USA	Caucasian	192/190	>0.05	7	54	131	5	52	13
Edinburgh <sup>a</sup>	UK	Caucasian	368/284	>0.05	11	104	253	9	85	19

HWE = Hardy-Weinberg equilibrium. <sup>a</sup>Genome-wide association study data from Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (Ripke et al., 2011).

# Association between miR-137 rs1625579 and schizophrenia susceptibility

As no heterogeneity was detected under any genetic model (P > 0.10 and  $I^2 < 50\%$ ), the fixed-effect model was used. As shown in Figure 2, there was a statistically significant difference between miR-137 rs1625579 alleles and genotypes in terms of schizophrenia susceptibility under the allelic (T *vs* G: OR = 1.15, 95%CI = 1.10-1.21, P < 0.001) and the homogeneous codominant models (TT *vs* GG: OR = 1.32, 95%CI = 1.13-1.54, P < 0.001), but no such association was observed under the heterogeneous codominant model (GT *vs* GG: OR = 1.14, 95%CI = 0.97-1.34, P = 0.11). A  $\lambda$  value of 0.46 (95%CI = 0.028-0.942) suggested that a codominant inheritance mode was most likely. Sensitivity analysis (Table S2) showed that removal of any given article did not result in a significant change to the OR, suggesting that our results are reasonably stable.

A stratified analysis based on World Health Organization (WHO) regions (Table S3) revealed the same association under allelic and codominant models in the European region (T vs G: OR = 1.15, 95%CI = 1.09-1.22, P < 0.001; TT vs GG: OR = 1.31, 95%CI = 1.10-1.58, P = 0.002; GT vs GG: OR = 1.12, 95%CI = 0.94-1.34, P = 0.20), but not in the Western Pacific (T vs G: OR = 1.17, 95%CI = 1.04-1.31, P = 0.009; TT vs GG: OR = 1.49, 95%CI = 0.95-2.35, P = 0.08; GT vs GG: OR = 1.28, 95%CI = 0.80-2.05, P = 0.30) or the Americas (T vs G: OR = 1.09, 95%CI = 0.90-1.33, P = 0.36; TT vs GG: OR = 1.20, 95%CI = 0.66-2.16, P = 0.55; GT vs GG: OR = 1.11, 95%CI = 0.60-2.03, P = 0.75). This suggests that no clear relationship exists between rs1625579 and schizophrenia among populations of these latter two regions.

Genetics and Molecular Research 15 (3): gmr.15038703

Study or Subgroup	Case	Total	Cont	rol Total		Odds Ratio	Odds Ratio
Yuan 2015	Events 949	Total 1012	Events 986	1040	Weight 2.1%	M-H. Fixed. 95% C 0.82 [0.57, 1.20]	
GWAS-Hillside 2011	316	384	318	380	2.0%	0.91 [0.62, 1.32]	i —
GWAS-TOP3 2011	391	496	557	702	3.4%	0.97 [0.73, 1.29]	
Sun 2015 Rose 2014	1096 273	1178 326	1159 251	1244 300	2.8%	0.98 [0.72, 1.34]	
GWAS-Bonn 2011	755	948	2058	2608	7.8%	1.05 [0.87, 1.26]	
GWAS-Edinburgh 2011	610	736	465	568	3.2%	1.07 [0.80, 1.43]	i +-
GWAS-CATIE 2011	665	804	338	414	2.7%	1.08 [0.79, 1.46]	
Green 2013	791 157	982 168	519 117	656 126	4.3% 0.3%	1.09 [0.85, 1.40] 1.10 [0.44, 2.74]	
Kuswanto 2015 GWAS-Munich 2011	157	168	117 556	126 702	0.3%	1.10 [0.44, 2.74]	
GWAS-WUNICH 2011 GWAS-UK 2011	702	944	4736	5868	4.1%	1.11 [0.93, 1.33]	
Strazisar 2015	653	814	1301	1664	5.9%	1.13 [0.92, 1.39]	i +
Wang 2014	569	600	565	600	1.0%	1.14 [0.69, 1.87]	
GWAS-Portugal 2011	591	692	358	430	2.3%	1.18 [0.85, 1.64]	
GWAS-Swedish2 2011 GWAS-Aberdeen 2011	618 1196	780 1440	348 1120	458 1396	3.2% 6.8%	1.21 [0.92, 1.59]	T_
Lett 2013	840	1020	192	242	1.9%	1.22 [0.86, 1.73]	
GWAS-London 2011	861	1036	787	982	4.8%	1.22 [0.97, 1.53]	
Guan 2014	2519	2858	2694	3140	10.7%	1.23 [1.06, 1.43]	
GWAS-UCLA 2011	1165	1408	1004	1262	6.4%	1.23 [1.01, 1.50]	
GWAS-Copenhagen 2011 GWAS-Swedish1 2011	777	964 336	700 256	914 334	4.9%	1.27 [1.02, 1.58]	
GWAS-Cardiff 2011	863	1054	236 947	1218	5.6%	1.29 [1.05, 1.59]	
Ma 2014	1159	1222	1164	1256	2.1%	1.45 [1.04, 2.02]	
van Erp 2014	87	96	107	126	0.3%	1.72 [0.74, 3.98]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)		23166		28630	100.0%	1.15 [1.10, 1.21]	•
Total events Heterogeneity: Chi <sup>2</sup> = 16.25,	19651		23603				
Heterogeneity: Chi <sup>4</sup> = 16.25, Test for overall effect: Z = 5.	, df = 25 (P 55 /P ≤ 0.0	= 0.91) 0001)	; I* = 0%				0.1 0.2 0.5 1 2 5 10
Test for overall effect. 2 = 5.	.00 (F < 0.0	0001)					Favors [case] Favors [control]
3	Case		Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup			Events		Weight	M-H, Fixed, 95% C	
Wang 2014	269	269	265	265		Not estimable	
van Erp 2014	39	39	46	48	0.2%	4.25 [0.20, 91.12]	
Kuswanto 2015	74	75	56	58	0.3%	2.64 [0.23, 29.88]	
Rose 2014	112	114	105	109	0.7%	2.13 [0.38, 11.89]	
Ma 2014 Yuan 2015	550 445	552 447	541 466	546 466	0.7% 0.9%	2.54 [0.49, 13.16]	·
Yuan 2015 Lett 2013	445 344	447 358	466	466 81	0.9% 1.7%	0.19 [0.01, 3.99]	
GWAS-Portugal 2011	344 252	358 259	76 149	81 155	1.7%	1.62 [0.57, 4.62] 1.45 [0.48, 4.39]	
Sun 2015	252 512	259 517	540	543	1.8%	0.57 [0.14, 2.39]	
GWAS-Swedish1 2011	109	115	98	107	1.8%	1.67 [0.14, 2.39]	
GWAS-Hillside 2011	131	138	133	138	2.4%	0.70 [0.22, 2.27]	
GWAS-CATIE 2011	275	287	138	145	2.7%	1.16 [0.45, 3.02]	
GWAS-Edinburgh 2011	253	264	190	199	3.2%	1.09 [0.44, 2.68]	
GWAS-Swedish2 2011	245	262	132	145	3.9%	1.42 [0.67, 3.01]	
GWAS-TOP3 2011	154	165	221	236	4.3%	0.95 [0.42, 2.12]	
GWAS-Munich 2011	284	300	220	235	4.7%	1.21 [0.59, 2.50]	
GWAS-London 2011	358	373	315	334	4.7%	1.44 [0.72, 2.88]	
Green 2013	319	338	205	219	5.0%	1.15 [0.56, 2.34]	
GWAS-Copenhagen 2011	313	331	268	293	5.5%	1.62 [0.87, 3.04]	·
GWAS-Cardiff 2011	353	370	368	398	5.8%	1.69 [0.92, 3.12]	
GWAS-UCLA 2011	482	503	399	425	6.4%	1.50 [0.83, 2.70]	
GWAS-Aberdeen 2011	497	518	449	476	6.7%	1.42 [0.79, 2.55]	T
Guan 2014	1111	1132	1162	1200	7.4%	1.73 [1.01, 2.97]	
	320	335 288	1911 513	2020 557	8.6% 9.0%	1.22 [0.70, 2.11] 1.09 [0.64, 1.87]	
GWAS-UK 2011	067			870	9.0%	1.07 [0.64, 1.87]	
GWAS-UK 2011 Strazisar 2015	267	224		870	9.170	1.07 [0.64, 1.62]	
GWAS-UK 2011	267 301	321	812				
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011	301			10268	100.0%	1.32 [1.13, 1.54]	•
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI)	301	321 8670		10268	100.0%	1.32 [1.13, 1.54]	•
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70,	301 8369 , df = 24 (P	8670 = 0.99	9778		100.0%	1.32 [1.13, 1.54]	
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI)	301 8369 , df = 24 (P	8670 = 0.99	9778		100.0%	1.32 [1.13, 1.54]	0.01 0.1 1 10 100
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70,	301 8369 , df = 24 (P	8670 = 0.99	9778		100.0%	1.32 [1.13, 1.54]	
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3.	301 8369 , df = 24 (P	8670 = 0.99	9778		100.0%	1.32 [1.13, 1.54]	0.01 0.1 1 10 100
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70,	301 8369 , df = 24 (P	8670 = 0.99] 004)	9778			Odds Ratio	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3.	301 8369 , df = 24 (P .51 (P = 0.0	8670 = 0.99) 004) e	9778 ; I <sup>z</sup> = 0%	rol	100.0% Weight		0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Tota (95% CI) Total events Heterogeneity: Chi <sup>p</sup> = 10.70, Test for overall effect: Z = 3.	301 8369 , df = 24 (P .51 (P = 0.0 Cas <u>Events</u>	8670 = 0.99) 004) e	9778 ; I <sup>2</sup> = 0% Cont	rol		Odds Ratio M-H. Fixed. 95% Cl	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3.	301 8369 , df = 24 (P .51 (P = 0.0 Cas	8670 = 0.99) 004) e <u>Total</u>	9778 ; I <sup>2</sup> = 0% Cont <u>Events</u>	rol Total 35		Odds Ratio <u>M-H. Fixed, 95% Cl</u> Not estimable	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazisar 2015 GWAS-Bonn 2011 Total (96% Ct) Total events Heterogeneity: Chi <sup>2</sup> = 10.70. Test for overall effect: Z = 3. <u>Study or Subgroup</u> Wang 2014 van Erp 2014	301 8369 , df = 24 (P .51 (P = 0.0 Cas <u>Events</u> 31	8670 = 0.99) 004) e <u>Total</u> 31	9778 ; I <sup>2</sup> = 0% <u>Cont</u> <u>Events</u> 35	rol Total	Weight	Odds Ratio <u>M-H, Fixed, 95% CJ</u> Not estimable 3.06 (0.13, 70.94]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Swazisar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3. 	301 8369 , df = 24 (P .51 (P = 0.0 Cas <u>Events</u> 31 9	8670 = 0.99) 004) e <u>Total</u> 31 9 10	9778 ;   <sup>2</sup> = 0% Cont <u>Events</u> 35 15	rol Total 35 17	<u>Weight</u> 0.2% 0.2%	Odds Ratio M-H. Fixed. 95% Cl Not estimable 3.06 [0.13, 70.94] 3.60 [0.26, 50.33]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Strazlar 2015 GWA5-Bonn 2011 GWA5-Bonn 2011 Total densk Chi Total densk Chi Test for overall effect: Z = 3. <u>Study or Subgroup</u> Wang 2014 van Erp 2014 Kuswanto 2015 Rose 2014	301 8369 , df = 24 (P .51 (P = 0.0 Cas- <u>Events</u> 31 9 9	8670 = 0.99) 004) e <u>Total</u> 31 9	9778 ; I <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5	rol <u>Total</u> 35 17 7	Weight 0.2% 0.2% 0.6%	Odds Ratio M-H. Fixed. 95% Cl Not estimable 3.06 (0.13, 70.94) 3.60 (0.26, 50.33) 2.39 (0.42, 13.72)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Strazisar 2015 GWA5-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3. 	301 8369 , df = 24 (P .51 (P = 0.0 Cas <u>Events</u> 31 9 9 9 9 59	8670 = 0.99) 004) e <u>Total</u> 31 9 10 51	9778 ; i <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5 41	rol <u>Total</u> 35 17 7 45	Weight 0.2% 0.6% 0.8%	Odds Ratio M-H. Fixed, 95% C Not estimable 3.06 (0.26, 50.33) 2.39 (0.42, 13.72) 1.80 (0.34, 9.59)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 GWA5-Bacnn 2011 GWA5-Bacnn 2011 GWA5-Bacnn 2011 Total densk Childreensk Heterogeneity: Chill = 10,70, Test for overall effect: Z = 3. Study or Subgroup Wang 2014 van Etp 2014 Kuswanto 2015 Rose 2014 Ma 2014 Yuan 2015	301 8369 , df = 24 (P .51 (P = 0.0 Cas Events 31 9 9 9 49 59 59	8670 = 0.99) 004) e <u>Total</u> 31 9 10 51 61 61	9778 ;   <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5 41 82 54	rol <u>Total</u> 35 17 7 45 87 54	Weight 0.2% 0.6% 0.8% 0.8%	Odds Ratio M-H. Fixed. 95% CI Not estimable 3.06 (0.13, 70.94] 3.60 (0.26, 50.33) 2.39 [0.42, 13,72] 1.80 (0.34, 9.59] 0.22 [0.01, 4.65]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Straziara 2015 GWA5-Bonn 2011 Total 995% CI) Total events Inteleropaneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3. 	301 8369 , df = 24 (P .51 (P = 0.0 Cas <u>Events</u> 31 9 9 9 9 59	8670 = 0.99] 004) e <u>Total</u> 31 9 10 51 61 61 77	9778 ;   <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5 41 82	rol Total 35 17 7 45 87	Weight 0.2% 0.6% 0.8%	Odds Ratio M-H. Fixed, 95% C Not estimable 3.06 (0.26, 50.33) 2.39 (0.42, 13.72) 1.80 (0.34, 9.59)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 GWA5-Bachn 2011 GWA5-Bachn 2011 GWA5-Bachn 2011 Total sensis Heterogeneity: ChP = 10,70, Test for overall effect: Z = 3. <u>Study or Subgroup</u> Wang 2014 van Erp 2014 Kuswanto 2015 Sun 2015 Sun 2015 Sun 2015 Sun 2015	301 8369 , df = 24 (P 5.51 (P = 0.0 Cass Events 31 9 9 9 9 9 9 9 9 9 9 9 59 59 59 72 87	8670 = 0.99) 004) e <u>Total</u> 31 31 9 10 51 61 61 77 94	9778 ; I <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5 41 82 54 79 60	rol <u>Total</u> 35 17 7 45 87 54 82 66	Weight 0.2% 0.6% 0.8% 1.7% 1.8%	Odds Ratio M-H. Fixed, 95% CI Not estimable 3.60 (0.13, 70.94) 3.60 (0.26, 50.33) 2.39 (0.42, 13.72) 1.80 (0.34, 9.59) 0.22 (0.01, 4.65) 0.55 (0.13, 2.37) 1.24 (0.40, 3.88)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Straziara 2015 GWA5-Benn 2011 Total 995% CI) Total events Inteleropaneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3. 	301 8369 . df = 24 (P .51 (P = 0.0 Cass <u>Events</u> 31 9 9 9 9 9 59 59 59 59 59 72 87 2 87	8670 = 0.99) 004) e <u>Total</u> 31 31 9 10 51 61 61 61 77 94 166	9778 ;   <sup>2</sup> = 0% Cont Events 35 15 5 41 82 54 79 60 40	rol 35 17 45 87 54 82 66 45	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 1.8% 1.9%	Odds Ratio M-H. Fixed, 35% Cf 3.06 [0.13, 70.94] 3.60 [0.26, 50.33] 2.39 [0.42, 13.72] 1.80 [0.34, 9.59] 0.22 [0.01, 4.65] 0.55 [0.13, 2.37] 1.24 [0.40, 3.88] 1.36 [0.46, 3.99]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 GWA5-Bacnn 2011 GWA5-Bacnn 2011 GWA5-Bacnn 2011 Total sensis Heterogeneity: CriP = 10,70, Test for overall effect: Z = 3. <u>Study or Subgroup</u> Wang 2014 van Erp 2014 Kuswanto 2015 Sun 2015 Sun 2015 Sun 2015 GWA5-Portugal 2011 Lett 2013 GWA5-Portugal 2011	301 8369 df = 24 (P 51 (P = 0.0 Cas Events 31 9 9 9 9 9 9 9 9 9 72 87 72 87 152 53	8670 = 0.99) 004) e <u>Total</u> 31 9 10 51 61 61 61 61 77 94 166 59	9778 ;   <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5 41 82 54 79 60 40 60	rol 355 17 7 45 87 54 82 66 45 69	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 1.8% 1.9% 2.0%	Odds Ratio Not estimable 3.06 [0.13, 70,94] 3.60 [0.26, 50,33] 3.99 [0.42, 13,72] 1.80 [0.34, 9.59] 0.22 [0.01, 4.65] 0.55 [0.13, 2.37] 1.24 [0.40, 0.38] 1.36 [0.46, 3.99] 1.32 [0.44, 3.97]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlar: 2015 GWAS-Bonn 2011 Total 995% CI) Total events Intelerogeneity: Chi <sup>2</sup> = 10.70, Test for overall effect: Z = 3. <u>Study: or Subgroup</u> Wang 2014 van Ep 2014 Vang 2014 Yuan 2015 Sun 2015 GWAS-Portugal 2011 Lett 2013 GWAS-Swediat2 2011 GWAS-Swediat2 2011	301 8369 , df = 24 (P = 0.0 Cass Events Events 1 9 9 9 9 9 59 59 59 72 87 752 87 53 54	8670 = 0.99) 0004) e <u>Total</u> 31 9 10 51 61 61 61 77 9 4 166 59 61	9778 ;   <sup>2</sup> = 0% Cont <u>Events</u> 35 15 5 41 82 54 79 60 40 60 52	rol Total 35 17 7 45 87 54 87 54 82 66 45 69 57	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 1.8% 1.9% 2.0% 2.2%	Odds Ratio M-H. Fixed, 35% Cf Not estimable 3.06 (0.26, 50.34) 3.69 (0.24, 13.72) 1.80 (0.34, 9.59) 0.22 (0.01, 4.65) 0.55 (0.13, 2.37) 1.24 (0.40, 3.89) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Swazisar 2015 GWA5-Bonn 2011 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 10.70; Test for overall effect: Z = 3. <u>Study or Subgroup</u> Wang 2014 wan Eig 2014 Wang 2014 Wang 2014 Wang 2015 Sun 2015 Sun 2015 Sun 2015 Sun 2015 Sun 2015 Sun 2015 GWA5-Portugal 2011 Left 2013 GWA5-Sweisin2 2011 GWA5-Sweisin2 2011 GWA5-Carte 2011	301 8369 . df = 24 (P .51 (P = 0.0 Cass Events 31 9 9 9 9 9 9 9 9 72 87 7 152 87 7 152 53 54 115	8670 = 0.99) 0004) * * * * * * * * * * * * * * * * * * *	9778 (1 <sup>2</sup> = 0%) Cont Events 35 15 5 41 82 54 41 82 54 41 82 54 40 60 60 52 62 62	rol Total 35 17 7 45 87 54 82 65 45 69 57 69	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 1.8% 1.9% 2.0% 2.2% 2.7%	Odds Ratio Not estimable 3.06 [0.13, 70, 94] 3.60 [0.26, 50, 33] 3.89 [0.42, 13, 72] 1.80 [0.34, 9.59] 0.22 [0.01, 4.65] 0.55 [0.13, 2.37] 1.24 [0.40, 3.88] 1.36 [0.46, 3.99] 0.74 [0.22, 2.49] 0.74 [0.22, 2.49]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Straziara 2015 GWAS-Bonn 2011 Total 95% CI) Total events Teat for overall effect: Z = 3. Study or Subgroup Wang 2014 Van Erp 2014 Kuswanto 2015 Rose 2014 Ma 2014 Yuan 2015 Sun 2015 GWAS-Portugal 2011 Left 2013 GWAS-Swedish2 2011 GWAS-Simba 2011 GWAS-CATIE 2011 GWAS-CATIE 2011	301 8369 , df = 24 (P = 0.0 Cas Events 31 9 9 9 9 72 87 152 53 54 115 104	8670 = 0.99) 004) * <u>Total</u> 31 9 10 51 61 61 61 77 94 166 59 9 127 115	9778 5 1 <sup>2</sup> = 0% Cont Events 35 15 5 41 82 54 79 60 40 60 52 62 85	rol <u>Total</u> 35 17 45 87 54 82 66 45 69 57 69 94	Weight 0.2% 0.6% 0.8% 1.7% 1.8% 1.9% 2.0% 2.7% 3.1%	Odds Ratio M-H. Fixed. 95% Cl Not estimable 3.06 (0.13, 70.94) 2.39 (0.42, 13.72) 1.80 (0.34, 9.59) 0.22 (0.01, 465) 0.25 (0.13, 2.37) 1.24 (0.40, 3.89) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.44, 2.87) 1.07 (10.02, 2.249)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 GWA5-Bacnn 2011 GWA5-Bacnn 2011 GWA5-Bacnn 2011 Total sensis Heterogeneity: CriP = 10,70, Test for overall effect: 2 = 3. <u>Study or Subgroup</u> Wang 2014 van Erp 2014 Kuswanto 2015 Sun 2015 Sun 2015 Sun 2015 GWA5-Portugal 2011 Lett 2013 GWA5-Cortugal 2011 GWA5-Cortugal 2011 GWA5-Cortugal 2011 GWA5-Cortugal 2011 GWA5-Cortugal 2011 GWA5-Cortugal 2011	301 8369 , df = 24 (P. 51 (P = 0.0 Cas Events 31 9 9 9 9 9 9 9 9 9 9 9 9 9 9 72 59 72 59 72 59 72 53 354 115 152 53 54 87	8670 = 0.99) 004) * * * * * * * * * * * * * * * * * * *	9778 578 578 578 579 579 600 400 600 522 622 855 115	rol <u>Total</u> 35 17 7 54 87 54 82 66 45 69 57 69 94 130	Weight 0.2% 0.6% 0.8% 1.7% 1.8% 1.9% 2.0% 2.2% 3.1% 4.0%	Odds Ratio MH, Fixed. 95% CJ Not estimable 3.66 [0.13, 70.94] 3.80 [0.26, 50.33] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.99] 1.32 [0.44, 3.97] 0.74 [0.22, 2.49] 1.00 [0.40, 2.53] 0.98 [0.43, 2.25]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Straziara 2015 GWA5-Bonn 2011 Total 990% CI) Total events Teat for overall effect: Z = 3. Study or Subgroup Wang 2014 Van Erp 2014 Kuswanto 2015 Rose 2014 Ma 2014 Yuan 2015 Sun 2015 GWA5-Portugal 2011 GWA5-Waite 2011 GWA5-Waite 2011 GWA5-TOP3 2011 GWA5-TOP3 2011 GWA5-TOP3 2011	301 8369 , df = 24 (P .51 (P = 0.0 Cas- Events 31 9 9 9 9 9 9 9 9 9 9 79 2 87 71 52 53 54 115 104 83 128	8670 = 0.99 004)	9778 );   <sup>2</sup> = 0% Cont Events 35 5 41 82 54 79 60 40 60 60 52 62 85 115 84	rol <u>Total</u> 35 17 7 45 87 54 82 66 45 69 95 7 69 94 93 130 97	Weight 0.2% 0.6% 0.8% 1.7% 1.8% 1.9% 2.0% 2.2% 2.7% 3.1% 4.0%	Odds Ratio M-H. Fixed, 95% Cl Not estimable 3.06 (0.13, 70.94) 3.69 (0.26, 50.33) 1.80 (0.34, 9.59) 0.22 (0.01, 465) 0.55 (0.13, 2.37) 1.24 (0.40, 3.89) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 1.36 (0.44, 2.83) 1.00 [0.40, 2.53) 0.98 (0.43, 2.25) 0.98 (0.43, 2.25)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Strażlar 2015 GWA5-Bonn 2011 Total (95% CI) Total events Intercomenty: Chi <sup>p</sup> = 10.70, Test for overall effect: Z = 3, Study or Stubgroup Wang 2014 van Erp 2014 Kuswanto 2015 Rose 2014 Yuan 2015 Sun 2015 GWA5-Portugal 2011 Lett 2013 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011 GWA5-Sherti 2011	301 8369 , df = 24 (P .51 (P = 0.0 Cass Events 31 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99 004) = Total 31 9 10 51 61 61 61 61 61 61 77 94 166 59 61 127 115 94 145 150	9778 (;   <sup>2</sup> = 0%) Contr Events 355 55 55 55 55 55 55 55 55 54 40 40 40 40 60 22 52 62 85 51 155 54 116 117 118 118 118 118 118 118 118 118 118	rol <u>Total</u> 35 17 7 45 82 66 45 69 57 69 94 130 97 131	Weight 0.2% 0.6% 0.8% 1.7% 1.8% 2.0% 2.2% 3.1% 4.0% 4.6%	Odds Ratio MH, Fixed. 95% Cl Not estimable 3.66 [0.13, 70.94] 3.80 [0.26, 50.33] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.99] 1.32 [0.44, 3.97] 0.74 [0.42, 2.49] 1.08 [0.47, 2.89] 1.09 [0.40, 2.53] 1.71 [0.54, 2.52] 1.71 [0.54, 2.52]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Strazlar 2015 GWA5-Bonn 2011 Total 990% CI) Total 990% CI Total 990% CI Subdy of Subgroup Wang 2014 Wan Erp 2014 Kuswanto 2015 Sun 2015 Sun 2015 GWA5-Portugal 2011 Left 2013 GWA5-Simble 2011 GWA5-Simble 2011 GWA5-GTIPE 2011 GWA5-Simble 2011	301 8369 , df = 24 (P .51 (P = 0.0 Cas Events 31 9 9 9 9 9 9 9 9 9 9 9 72 87 72 87 59 59 59 59 59 59 59 59 59 59 152 53 54 115 104 83 128 104 83 128 104 104 104 104 104 105 105 105 105 105 105 105 105 105 105	8670 = 0.99 0004)	9778 9778 Cont Events 35 15 5 41 82 42 79 60 40 00 52 62 85 15 5 41 82 41 82 41 82 82 82 82 82 82 82 82 82 82	rol <u>Total</u> 35 17 7 45 87 45 87 45 86 45 57 69 94 130 97 131 176	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 1.8% 1.9% 2.0% 2.2% 2.7% 3.1% 4.0% 4.0% 4.2% 4.9%	Odds Ratio M-H. Fixed, 35% Cl Not estimable 3.06 [0.13, 70.94] 3.09 [0.24, 13, 72] 1.80 [0.24, 50.39] 0.22 [0.01, 4.65] 0.25 [0.13, 2.37] 1.24 [0.40, 3.89] 1.35 [0.46, 3.89] 1.32 [0.44, 3.87] 1.36 [0.47, 2.83] 1.00 [0.47, 2.53] 0.98 [0.57, 2.39]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strażlar 2015 GWAS-Benn 2011 Total (95% CI) Total events Intel events Intel events Study or Subgroup Wang 2014 van Erp 2014 Vang 2014	301 8369 , df = 24 (P 5.51 (P = 0.0 Cass Events 31 9 9 9 9 59 59 59 59 59 59 59 59 59 59 5	8670 = 0.993 0004) Total 9 10 51 61 61 61 777 94 165 59 61 1277 115 59 41 145 150 0 160 172	9778 55 55 55 55 55 55 55 55 55 55 55 55 55	rol <u>Total</u> 35 17 7 7 45 87 45 87 45 87 69 957 69 94 130 97 131 176 123	Weight 0.2% 0.6% 0.8% 1.7% 2.0% 2.7% 3.1% 4.0% 4.2% 4.6% 4.9%	Odds Ratio MH, Fixed, 95% C Not estimable 3.66 (0.13, 70.94) 3.80 (0.24, 50.72) 1.80 (0.34, 9.59) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 1.24 (0.40, 0.38) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 0.74 (0.22, 2.49) 1.32 (0.54, 3.52) 1.71 (0.54, 2.52) 1.71 (0.57, 2.39) 1.33 (0.50, 2.15)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Total events Test for overall effect: Z = 3. Study or Stubgroup Wang 2014 van Erp 2014 Kuswanic 2015 Rose 2014 Ma 2014 Yuan 2015 Sun 2015 GWAS-Portugal 2011 Left 2013 GWAS-Servedish2 2011 GWAS-Servedish2 2011	301 8369 . df = 24 (P .51 (P = 0.0 Cass Events 31 9 9 9 9 9 9 9 9 9 9 9 72 87 71 52 53 54 4115 104 83 128 134 145 153	8670 = 0.993 0004)	9778 5 (;   <sup>2</sup> = 0% <b>Cont</b> <b>Events</b> 355 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	rol <u>Total</u> 35 17 7 45 87 54 82 66 45 57 69 94 130 97 131 176 123 189	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 1.8% 1.9% 2.2% 2.7% 3.1% 4.0% 4.2% 4.6% 4.9% 5.8%	Odds Ratio M-H. Fixed. 35% Cl Not estimable 3.06 [0.13, 70.94] 3.69 [0.26, 50.33] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 0.25 [0.13, 2.37] 1.24 [0.40, 3.88] 1.36 [0.46, 3.99] 1.32 [0.44, 3.97] 1.36 [0.44, 3.99] 1.32 [0.44, 3.97] 1.36 [0.44, 2.83] 0.74 [0.22, 2.49] 1.00 [0.40, 2.53] 0.98 [0.43, 2.25] 1.00 [0.40, 2.53] 0.98 [0.57, 2.39] 1.37 [0.57, 2.39] 1.38 [0.57, 2.44]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strażlar 2015 GWAS-Benn 2011 Total 996% CI) Total events Intel events Intel events Study or Subgroup Wang 2014 van Ep 2014 Wang 2014 Vang 2014	301 8369 . df = 24 (P .51 (P = 0.0 Cass Events 31 9 9 9 9 9 9 9 59 72 53 53 54 1155 104 83 128 83 128 83 128 134 145 153	8670 = 0.99 004) = <u>Total</u> 31 9 10 51 61 61 61 61 61 61 61 61 61 127 115 94 145 120 160 150 160 172 169	9778 Cont Events 5 5 5 5 5 5 5 5 5 5 5 5 5	rol <u>Total</u> 35 17 7 45 87 54 82 66 45 69 94 130 94 130 176 123 131 176 123 131 176 123 131 176 135 177 177 177 177 177 177 177 17	Weight 0.2% 0.6% 0.8% 1.7% 1.8% 2.0% 2.7% 3.1% 4.0% 4.2% 4.9% 4.9% 5.8% 6.1%	Odds Ratio MH, Fixed, 95% C Not estimable 3.66 (0.13, 70.94) 3.80 (0.26, 50.33) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 1.24 (0.40, 0.38) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 0.74 (0.22, 2.49) 1.09 (0.41, 2.89) 1.00 (0.40, 2.53) 1.71 (0.54, 2.52) 1.71 (0.54, 2.52) 1.71 (0.57, 2.39) 1.03 (0.50, 2.15) 1.28 (0.67, 2.44) 1.31 (0.70, 2.47)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlar 2015 GWAS-Bonn 2011 Total (96% CI) Total events Total events Trat for overnall effect: Z = 3. Study or Subgroup Wang 2014 van Etp 2014 Kuswanto 2015 Sun	301 8369 . df = 24 (P = 0.0 Cass Events 31 9 9 49 59 59 59 59 59 59 59 59 59 59 59 59 59	8670 = 0.99) 004) 31 31 9 10 51 61 61 61 66 51 66 61 127 71 55 60 1127 115 150 010 112 145 150 010 172 169 9 174	9778 (; ) <sup>2</sup> = 0% <b>Contt</b> <b>Events</b> 35 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 355 17 7 45 87 7 45 87 84 82 66 45 69 94 130 97 131 176 123 189 241 176 177 130 177 131 130 177 135 137 137 137 137 137 137 137 137	Weight 0.2% 0.6% 0.8% 1.7% 1.8% 1.8% 1.8% 2.2% 2.2% 3.1% 4.0% 4.6% 4.6% 4.2% 5.8% 5.8%	Odds Ratio M-H. Fixed. 35% Cl Not estimable 3.06 [0.13, 70.94] 3.09 [0.24, 50.30] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.86] 1.32 [0.44, 3.97] 1.36 [0.46, 3.98] 1.32 [0.44, 3.97] 1.00 [0.40, 2.53] 0.98 [0.43, 2.25] 1.00 [0.40, 2.53] 0.98 [0.43, 2.25] 1.00 [0.40, 2.53] 1.00 [0.40, 2.53] 1.00 [0.45, 2.52] 1.00 [0.57, 2.39] 1.32 [0.57, 2.44] 1.31 [0.70, 2.47] 1.24 [0.66, 2.22]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA3-UK 2011 Strażlar 2015 GWA5-Benn 2011 Total 995% CI) Total events Intel events Study or Subgroup Wang 2014 van Ep 2014 Wang 2014 Vang 2015 Sung 2014 Vang 2014 Van	301 8369 . df = 24 (P. .51 (P = 0.0 Events 31 9 9 9 9 9 9 9 59 59 59 59 59 59 59 59 5	8670 = 0.99 004)	9778 9778 Cont Events 55 55 55 51 55 51 411 82 54 40 60 52 25 440 40 60 52 25 15 51 15 51 15 51 15 51 15 51 15 15	rol <u>Total</u> 355 17 7 45 87 45 87 45 86 45 69 94 45 69 94 130 97 131 176 123 189 241 249	Weight 0.2% 0.6% 0.8% 0.8% 1.7% 2.0% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7	Odds Ratio MH, Fixed, 95% C Not estimable 3.66 (0.13, 70.94) 3.80 (0.26, 50.33) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 1.24 (0.40, 0.38) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 0.74 (0.22, 2.49) 1.09 (0.41, 2.89) 1.09 (0.40, 2.53) 1.71 (0.54, 2.52) 1.71 (0.54, 2.52) 1.73 (0.57, 2.49) 1.33 (0.70, 2.47) 1.23 (0.67, 2.44) 1.33 (0.70, 2.47) 1.21 (0.66, 2.23)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlar 2015 GWAS-Bonn 2011 Total (95% CI) Total events Total events Trat for overnall effect: Z = 3. Study or Stubgroup Wang 2014 van Erp 2014 Kuswanto 2015 GWAS-Portugal 2011 Left 2013 GWAS-Portugal 2011 GWAS-Hortigal 2011 GWAS-Grottigal 2011 GWAS-Cartiff 2011 GWAS-Cartiff 2011 GWAS-Cartiff 2011 GWAS-Cartiff 2011 GWAS-Cartiff 2011 GWAS-Cartiff 2011 GWAS-Cartiff 2011 GWAS-Aberden 2011	301 8369 df = 24 (P(P = 0.0 Cass Events 551 (P = 0.0 31 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99) 004) Total 31 9 9 10 51 61 61 77 94 166 59 61 127 115 94 145 160 160 172 160 160 172 174 222 233 318	9778 (; P = 0% Contt Events 35 15 5 41 82 5 44 40 60 60 62 62 85 115 84 41 116 167 109 164 42 211 206 85 84 157 207 84 157 157 157 157 157 157 157 157	rol Total 35 17 7 45 82 66 65 45 69 94 130 94 130 94 131 176 123 131 176 241 232 249 040 8 06 8 06 9 9 9 4 131 177 17 17 17 17 17 17 17 17 17 17 17 1	Weight 0.2% 0.8% 0.8% 1.8% 2.2% 2.7% 2.2% 2.7% 4.0% 4.9% 4.9% 5.8% 6.7% 7.0%	Odds Ratio M-H. Fixed. 35% Cl Not estimable 3.06 [0.13, 70.94] 3.09 [0.24, 50.37] 1.80 [0.34, 9.59] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.89] 1.36 [0.46, 3.89] 1.36 [0.46, 3.29] 1.00 [0.40, 2.53] 0.96 [0.43, 2.25] 1.07 [0.45, 2.24] 1.07 [0.45, 2.52] 1.08 [0.45, 2.25] 1.08 [0.57, 2.49] 1.37 [0.57, 2.44] 1.31 [0.70, 2.47] 1.21 [0.66, 2.22] 1.71 [0.64, 2.25]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strażlar 2015 GWAS-Benn 2011 Total (95% CI) Total events Inteleropanetty: Chi <sup>p</sup> = 10.70, Test for overall effect: Z = 3. Study or Subgroup Wang 2014 vian Ep 2014 Kuswanio 2015 Rose 2014 Yuan 2015 Sun 2015 GWAS-Portugal 2011 Lett 2013 GWAS-Portugal 2011 GWAS-Portugal 2011 GWAS-GATIE 2011 GWAS-GATIE 2011 GWAS-GATIE 2011 GWAS-GATIE 2011 GWAS-Copenhage 1011 GWAS-Copenhage 1011 GWAS-Copenhage 1011 GWAS-Copenhage 2011 GWAS-Copenhage 2014 GWAS-Copenhage 2014	301 8369 df = 24 (P, 0 Cass 551 (P = 0.51 (P = 0.24 (P, 0 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99) 004) * * * * * * * * * * * * *	9778 9778 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 35 17 7 54 87 87 87 87 87 87 87 87 89 94 130 97 131 130 97 131 132 249 241 232 249 408 2021	Weight 0.2% 0.6% 0.8% 0.8% 1.9% 2.0% 4.2% 4.2% 4.9% 4.6% 4.9% 4.6% 6.1% 5.8% 6.1% 7.0% 7.0%	Odds Ratio MH. Fixed. 95% C Not estimable 3.66 (0.13, 70.94) 3.60 (0.26, 50.33) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 1.24 (0.40, 0.38) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 0.74 (0.22, 2.49) 1.09 (0.41, 2.89) 1.09 (0.42, 2.53) 1.71 (0.54, 2.52) 1.71 (0.54, 2.52) 1.71 (0.54, 2.52) 1.71 (0.57, 2.39) 1.73 (0.57, 2.44) 1.33 (0.70, 2.47) 1.21 (0.66, 2.22) 1.71 (0.66, 2.23) 1.71 (0.66, 2.23) 1.71 (0.66, 2.23) 1.71 (0.66, 2.23)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlare 2015 GWAS-Benn 2011 Total (95% CI) Total events Total events Total events Total events Total events Total events Study or Subgroup Wang 2014 van Erp 2014 Kuswanio 2015 GWAS-Portugal 2011 Left 2013 GWAS-Bortugal 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Cartifized 2014 GWAS-Cartifized 2014 GWAS-Cartifized 2014 GWAS-Cartifized 2015	301 8369 df = 24 (P( 55) (P = 0.55) (P = 0.55) 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99) 004) * Total 31 9 9 10 51 61 61 61 61 77 94 166 59 61 127 115 59 44 166 59 94 127 115 120 160 172 169 174 223 318 152 213 140	9778 9778 Cont Events 35 15 5 41 82 54 479 600 60 60 62 85 84 416 6157 1094 1211 2064 2212 370 914 4225 22370 914 14 275 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 35 17 7 45 82 66 65 45 69 94 130 94 130 94 131 176 123 131 176 241 232 249 040 8 06 8 06 9 9 9 4 131 177 17 17 17 17 17 17 17 17 17 17 17 1	Weight 0.2% 0.2% 0.8% 0.8% 1.9% 2.2% 2.2% 3.1% 4.0% 4.0% 4.2% 4.6% 4.4% 4.4% 4.6% 6.7% 7.0% 8.2%	Odds Ratio M-H. Fixed. 35% Cl Not estimable 3.06 [0.13, 70.94] 3.09 [0.24, 50.37] 1.80 [0.34, 5.59] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.89] 1.36 [0.46, 3.89] 1.36 [0.46, 3.29] 1.36 [0.46, 2.25] 1.37 [0.57, 2.39] 1.37 [0.57, 2.39] 1.37 [0.57, 2.39] 1.37 [0.57, 2.43] 1.37 [0.57, 2.43] 1.38 [0.57, 2.44] 1.37 [0.76, 2.44] 1.31 [0.70, 2.47] 1.21 [0.66, 2.22] 1.77 [0.64, 2.13] 1.45 [0.63, 2.53] 1.45 [0.62, 2.5] 1.45 [0.62, 1.59]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlare 2015 GWAS-Benn 2011 Total (95% CI) Total events Total events Total events Total events Total events Total events Study or Subgroup Wang 2014 van Erp 2014 Kuswanio 2015 GWAS-Portugal 2011 Left 2013 GWAS-Bortugal 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Cartifized 2014 GWAS-Cartifized 2014 GWAS-Cartifized 2014 GWAS-Cartifized 2015	301 8369 df = 24 (P, 0 Cass 551 (P = 0.51 (P = 0.24 (P, 0 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99) 004) * * * * * * * * * * * * *	9778 9778 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 35 17 7 54 87 87 87 87 87 87 87 87 89 94 130 97 131 130 97 131 132 249 241 232 249 408 2021	Weight 0.2% 0.6% 0.8% 0.8% 1.9% 2.0% 4.2% 4.2% 4.9% 4.6% 4.9% 4.6% 6.1% 5.8% 6.1% 7.0% 7.0%	Odds Ratio M-H. Fixed. 35% Cl Not estimable 3.06 [0.13, 70.94] 3.09 [0.24, 50.37] 1.80 [0.34, 5.59] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.89] 1.36 [0.46, 3.89] 1.36 [0.46, 3.29] 1.36 [0.46, 2.25] 1.37 [0.57, 2.39] 1.37 [0.57, 2.39] 1.37 [0.57, 2.39] 1.37 [0.57, 2.43] 1.37 [0.57, 2.43] 1.38 [0.57, 2.44] 1.37 [0.76, 2.44] 1.31 [0.70, 2.47] 1.21 [0.66, 2.22] 1.77 [0.64, 2.13] 1.45 [0.63, 2.53] 1.45 [0.62, 2.5] 1.45 [0.62, 1.59]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strażlar 2015 GWAS-Benn 2011 Total (95% CI) Total events Inteleropanetty: Chi <sup>p</sup> = 10.70, Test for overall effect: Z = 3. Study or Subgroup Wang 2014 vian Ep 2014 Kuswanio 2015 Rose 2014 Yuan 2015 Sun 2015 GWAS-Portugal 2011 Lett 2013 GWAS-Portugal 2011 GWAS-Portugal 2011 GWAS-GATIE 2011 GWAS-GATIE 2011 GWAS-GATIE 2011 GWAS-GATIE 2011 GWAS-Copenhage 1011 GWAS-Copenhage 1011 GWAS-Copenhage 1011 GWAS-Copenhage 2011 GWAS-Copenhage 2014 GWAS-Copenhage 2014	301 8369 df = 24 (P( 55) (P = 0.55) (P = 0.55) 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99) 004) * Total 31 9 9 10 51 61 61 61 61 77 94 166 59 61 127 115 59 44 166 59 94 127 115 120 160 172 169 174 223 318 152 213 140	9778 9778 Cont Events 35 15 5 41 82 54 479 600 60 60 62 85 84 416 6157 1094 1211 2064 2212 370 914 4225 22370 914 14 275 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 35 17 7 45 5 4 87 54 87 69 94 130 97 131 176 9 94 133 189 9241 1232 249 408 319	Weight 0.2% 0.2% 0.8% 0.8% 1.9% 2.2% 2.2% 3.1% 4.0% 4.0% 4.2% 4.6% 4.4% 4.4% 4.6% 6.7% 7.0% 8.2%	Odds Ratio MH. Fixed. 95% C Not estimable 3.66 (0.13, 70.94) 3.60 (0.26, 50.33) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 0.22 (0.01, 4.65) 1.24 (0.40, 0.38) 1.36 (0.46, 3.99) 1.32 (0.44, 3.97) 0.74 (0.22, 2.49) 1.09 (0.41, 2.89) 1.09 (0.42, 2.53) 1.71 (0.54, 2.52) 1.71 (0.54, 2.52) 1.71 (0.54, 2.52) 1.71 (0.57, 2.39) 1.73 (0.57, 2.44) 1.33 (0.70, 2.47) 1.21 (0.66, 2.22) 1.71 (0.66, 2.23) 1.71 (0.66, 2.23) 1.71 (0.66, 2.23) 1.71 (0.66, 2.23)	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strazlare 2015 GWAS-Benn 2011 Total (95% CI) Total events Total events Total events Total events Total events Total events Study or Subgroup Wang 2014 van Erp 2014 Kuswanio 2015 GWAS-Portugal 2011 Left 2013 GWAS-Bortugal 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Gratifized 2011 GWAS-Cartifized 2014 GWAS-Cartifized 2014 GWAS-Cartifized 2014 GWAS-Cartifized 2015	301 8369 df = 24 (P( 55) (P = 0.55) (P = 0.55) 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8670 = 0.99) 004) * Total 31 9 9 10 51 61 61 61 61 77 94 166 59 61 127 115 59 44 166 59 94 127 115 120 160 172 169 174 223 318 152 213 140	9778 9778 Cont Events 35 15 5 41 82 54 479 600 60 60 62 85 84 416 6157 1094 1211 2064 2212 370 914 4225 22370 914 14 275 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 35 17 7 45 5 4 87 54 87 69 94 130 97 131 176 9 94 133 189 9241 1232 249 408 319	Weight 0.2% 0.2% 0.8% 0.8% 1.9% 2.2% 2.2% 3.1% 4.0% 4.0% 4.2% 4.6% 4.4% 4.4% 4.6% 6.7% 7.0% 8.2%	Odds Ratio M-H. Fixed. 35% Cl Not estimable 3.06 [0.13, 70.94] 3.09 [0.24, 50.37] 1.80 [0.34, 5.59] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.89] 1.36 [0.46, 3.89] 1.36 [0.46, 3.29] 1.36 [0.46, 2.25] 1.37 [0.57, 2.39] 1.37 [0.57, 2.39] 1.37 [0.57, 2.39] 1.37 [0.57, 2.43] 1.37 [0.57, 2.43] 1.38 [0.57, 2.44] 1.37 [0.76, 2.44] 1.31 [0.70, 2.47] 1.21 [0.66, 2.22] 1.77 [0.64, 2.13] 1.45 [0.63, 2.53] 1.45 [0.62, 2.5] 1.45 [0.62, 1.59]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWA5-UK 2011 Strazlar 2015 GWA5-Benn 2011 Total (95% CI) Total events Total events Total events Total events Total events Total events Study or Subgroup Wang 2014 van Etp 2014 Kuswanio 2015 GWA5-Portugal 2011 Left 2013 GWA5-Bortugal 2011 GWA5-Hortugal 2011 GWA5-Grotugal 2011 GWA5-Carditl 2011 GWA5-Carditl 2011 GWA5-Carditl 2011 GWA5-Carditl 2011 GWA5-Carditl 2011 GWA5-Carditl 2011 GWA5-Carditl 2011 GWA5-Grotugal 2015 GWA5-Grotugal 2015 GWA5-Grotugal 2015	301 8369 df = 24 (P, 0 55 (P = 0.5 10 (P = 0.5))))))))))))))))))))))))))))))))))))	8670 = 0.99) 004) * Total 31 9 9 10 51 61 61 61 61 61 77 7 94 166 59 94 145 150 160 172 169 94 145 152 223 318 8 152 152 140 173	9778 9778 Cont Events 35 15 5 41 82 54 479 600 60 60 62 85 84 416 6157 1094 1211 2064 2212 370 914 4225 22370 914 14 275 5 5 5 5 5 5 5 5 5 5 5 5 5	rol Total 35 17 7 45 87 7 45 87 99 94 130 176 131 176 122 249 402 249 249 402 402 402 402 402 402 402 402	Weight 0.2% 0.6% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8	Odds Ratio M-H. Fixed. 35% C Not estimable 3.06 [0.13, 70.94] 3.09 [0.26, 50.33] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.89] 1.36 [0.46, 3.89] 1.39 [0.44, 3.97] 0.74 [0.22, 2.49] 1.30 [0.40, 2.53] 0.59 [0.43, 2.25] 1.47 [0.57, 2.39] 1.32 [0.45, 7, 2.44] 1.31 [0.7, 2.47] 1.24 [0.46, 2.22] 1.72 [0.66, 2.22] 1.74 [0.64, 2.23] 1.45 [0.62, 2.25] 1.45 [0.62, 2.53] 1.45 [0.62, 2.53] 1.45 [0.62, 1.56] 1.45 [0.62, 1.56]	0.01 0.1 1 10 100 Favors [Case] Favors [control]
GWAS-UK 2011 Strailer 2015 GWAS-Bann 2011 Total 99xhS CI) Total 99xhS CI) Total 99xhS Heterogeneity: Chi <sup>2</sup> = 10.70, Trast for overall effect: Z = 3. Study or Subgroup Wang 2014 van Ep 2014 Vang 2014 Vang 2014 Vang 2014 Yuan 2015 Sun 2015 GWAS-Portugal 2011 GWAS-Portugal 2011 GWAS-Portugal 2011 GWAS-Portugal 2011 GWAS-Swedish2 2011 GWAS-Swedish2 2011 GWAS-GATIE 2011 GWAS-Scartif 2011 GWAS-CATIE 2011 GWAS-Copeningen 2011 GWAS-GWAS-BWAS 2011 Straziare 2015 GWAS-BWAS 2011 Straziare 2015	301 8369 (d = 24 (P 0. Events 51 (P = 0. 51 (P = 0. 51)	8670 = 0.999 0004) Total 31 9 10 51 61 77 94 166 59 60 160 160 160 160 160 172 145 150 160 160 172 145 152 140 173 318 8 152 140	9778 9778 Cont Events 355 541 822 54 960 00 600 600 600 600 600 600 600 600	rol Total 35 17 7 45 87 7 45 87 99 94 130 176 131 176 122 249 402 249 249 402 402 402 402 402 402 402 402	Weight 0.2% 0.6% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8	Odds Ratio M-H. Fixed. 35% C Not estimable 3.06 [0.13, 70.94] 3.09 [0.26, 50.33] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 0.22 [0.01, 4.65] 1.24 [0.40, 3.88] 1.36 [0.46, 3.89] 1.36 [0.46, 3.89] 1.39 [0.44, 3.97] 0.74 [0.22, 2.49] 1.30 [0.40, 2.53] 0.59 [0.43, 2.25] 1.47 [0.57, 2.39] 1.32 [0.45, 7, 2.44] 1.31 [0.7, 2.47] 1.24 [0.46, 2.22] 1.72 [0.66, 2.22] 1.74 [0.64, 2.23] 1.45 [0.62, 2.25] 1.45 [0.62, 2.53] 1.45 [0.62, 2.53] 1.45 [0.62, 1.56] 1.45 [0.62, 1.56]	0.01 0.1 1 10 100 Favors [Case] Favors [control]


**Figure 2.** Forest plots concerning the association between miR-137 rs1625579 and schizophrenia. **A.** Allelic model (T *vs* G). **B.** Codominant model (TT *vs* GG). **C.** Codominant model (GT *vs* GG). M-H = Mantel-Haenszel; d.f. = degrees of freedom; CI = confidence interval;  $Chi^2 = chi$ -square; GWAS = genome-wide association study.

Genetics and Molecular Research 15 (3): gmr.15038703

M.L. Ou et al.

# **Publication bias**

The shapes of the funnel plots, including all studies, indicated the absence of any potential publication bias under the allelic and codominant models (TT *vs* GG and GT *vs* GG; Figure 3).



**Figure 3.** Begg's funnel plot of publication bias. **A.** Allelic model (T *vs* G). **B.** Codominant model (TT *vs* GG). **C.** Codominant model (GT *vs* GG). SE = standard error; OR = odds ratio.

Genetics and Molecular Research 15 (3): gmr.15038703

# DISCUSSION

This meta-analysis aimed to advance our understanding of the association between miR-137 rs1625579 and susceptibility to schizophrenia. Our data demonstrated that this polymorphism is significantly associated with increased schizophrenia risk. Individuals carrying the T allele had a 15% increased risk of developing this disease compared to those with the G allele. In addition, subjects carrying the rs1625579 TT genotype were at a 32% greater risk compared to those with the GG genotype. In the stratified analysis according to WHO regions, this same relationship was observed under the allelic and codominant models among studies from countries of the European region, but not in data from the Western Pacific or the Americas. As shown in Table S3, 95%CIs relating to these latter were wider than those observed using European studies, suggesting insufficient sample sizes for data from the Western Pacific and American regions.

This analysis based on population studies showed that the miR-137 polymorphism increases schizophrenia risk, which might provide some evidence to uncover the major genetic factors involved in the pathogenesis of schizophrenia. Moreover, such variants might serve as useful markers for schizophrenia screening, allowing carriers to be identified and provided with appropriate treatment at an early stage, improving the health mentally and psysically.

miR-137 is known to be a major regulator of the nervous system (Yin et al., 2014). Using bioinformatics, Wright et al. (2013) identified 1144 genes potentially targeted by this miRNA, of which 25 or more intersected with those listed in the SZGR schizophrenia gene resource database. In addition, they identified 26 miR-137-regulated genes associated with susceptibility to this disease. Sun et al. (2011) demonstrated that miR-137, revealed to be a target of TLX (a nuclear receptor transcription factor) and a novel upstream regulator of lysine-specific demethylase 1 (LSD1), forms a regulatory feedback loop with these proteins to maintain the dynamics of neural stem cell (NSC) proliferation and differentiation. TLX is an essential regulator maintaining adult NSCs in an undifferentiated and self-renewable state. It achieves this in part by recruiting and forming a complex with its corepressor LSD1, the first lysyl demethylase found to regulate histone methylation (Shi et al., 2004), before binding an miR-137 genomic region to inhibit methylation of pre-miR-137, thus downregulating expression of miR-137 (Sun et al., 2007, 2010, 2011). Remarkably, as a target of miR-137, expression of LSD1 is in turn inhibited by this miRNA. In addition, it has been shown that increased miR-137 expression leads to reduced NSC proliferation and accelerated neural differentiation in mice (Sun et al., 2011). Thus, miR-137 plays an important role in regulating these processes in NSCs. Moreover, it also participates in the control of signal transduction and neuronal maturation through effects on its target genes.

Neuronal maturation and communication lead to the establishment of functional neural circuits, and abnormalities in neural structure and function can cause brain disorders such as schizophrenia. The SNP rs1625579 is located in an intron of a primary miR-137 transcript, and may affect the expression or maturation of this miRNA (Saunders et al., 2007), thus resulting in alterations to brain function.

In our meta-analysis, the NOS quality assessment scores of all included studies were no lower than 6. Furthermore, sensitivity analysis suggested that our results were sufficiently robust, and no significant heterogeneity or publication bias was detected. In addition, this meta-analysis returned results consistent with the largest schizophrenia GWAS conducted. However, the present findings should be interpreted with caution owing to certain limitations.

Genetics and Molecular Research 15 (3): gmr.15038703

#### M.L. Ou et al.

First, all eligible investigations in English or Chinese were incorporated, but those published in other languages that may have met our study criteria were not included. Second, the majority of data were obtained from Asian and Caucasian populations, with black and African individuals being insufficiently represented. Additional studies are needed to investigate the influence of this SNP in other populations. Third, outcomes were based on individual unadjust

In summary, this meta-analysis supports a clear association between the miR-137 rs1625579 SNP and schizophrenia risk. A comprehensive evaluation of gene-gene and geneenvironment interactions should also be performed in future analysis.

## **Conflicts of interest**

The authors declare no conflict of interest.

# ACKNOWLEDGMENTS

Research supported in part by the National Natural Science Foundation of China (grants #30901249, #81101267, #81541070, #91543132), the Guangdong Natural Science Foundation (grants #10151063201000036, #S2011010002526, #2016A030313089), the Guangdong Province Medical Research Foundation (grants #A2014374, #A2015310), and the Project from Jinan University (grants #21612426, #21615426, #JNUPHPM2016001, #JNUPHPM2016002).

# REFERENCES

Cochrane (2014). The Cochrane collaboration. Available at [http://www.cochrane.org/]. Accessed June 2014.

- Green MJ, Cairns MJ, Wu J, Dragovic M, et al.; Australian Schizophrenia Research Bank (2013). Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. *Mol. Psychiatry* 18: 774-780. <u>http://dx.doi.org/10.1038/mp.2012.84</u>
- Guan F, Zhang B, Yan T, Li L, et al. (2014). MIR137 gene and target gene CACNA1C of miR-137 contribute to schizophrenia susceptibility in Han Chinese. *Schizophr: Res.* 152: 97-104. <u>http://dx.doi.org/10.1016/j.schres.2013.11.004</u>
- Hansen T, Olsen L, Lindow M, Jakobsen KD, et al. (2007). Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2: e873. <u>http://dx.doi.org/10.1371/journal.pone.0000873</u>
- Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http:// dx.doi.org/10.1002/sim.1186
- Hommers LG, Domschke K and Deckert J (2015). Heterogeneity and individuality: microRNAs in mental disorders. J Neural Transm (Vienna) 122: 79-97. <u>http://dx.doi.org/10.1007/s00702-014-1338-4</u>
- Kelly S, Morris DW, Mothersill O, Rose EJ, et al. (2014). Genome-wide schizophrenia variant at MIR137 does not impact white matter microstructure in healthy participants. *Neurosci. Lett.* 574: 6-10. <u>http://dx.doi.org/10.1016/j.neulet.2014.05.002</u>

Kosik KS (2006). The neuronal microRNA system. Nat. Rev. Neurosci. 7: 911-920. http://dx.doi.org/10.1038/nrn2037

- Kuswanto CN, Sum MY, Qiu A, Sitoh YY, et al. (2015). The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 168B: 317-326. <u>http://dx.doi.org/10.1002/ajmg.b.32314</u>
- Lett TA, Chakravarty MM, Felsky D, Brandl EJ, et al. (2013). The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. *Mol. Psychiatry* 18: 443-450. <u>http://dx.doi.org/10.1038/mp.2013.17</u>
- Liu ZW, Liu JL, An Y, Zhang L, et al. (2012). Association between Ser311Cys polymorphism in the dopamine D2 receptor gene and schizophrenia risk: a meta-analysis in Asian populations. *Genet. Mol. Res.* 11: 261-270. <u>http://dx.doi.org/10.4238/2012.February.8.1</u>
- Ma G, Yin J, Fu J, Luo X, et al. (2014). Association of a miRNA-137 polymorphism with schizophrenia in a Southern Chinese Han population. *BioMed Res. Int.* 2014: 751267. <u>http://dx.doi.org/10.1155/2014/751267</u>

Genetics and Molecular Research 15 (3): gmr.15038703

- McGrath J, Saha S, Chant D and Welham J (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol. Rev.* 30: 67-76. http://dx.doi.org/10.1093/epirev/mxn001
- McGuffin P and Gottesman II (1999). Risk factors for schizophrenia. N. Engl. J. Med. 341: 370-371, author reply 372. http://dx.doi.org/10.1056/NEJM199907293410513
- Minelli C, Thompson JR, Abrams KR, Thakkinstian A, et al. (2005). The choice of a genetic model in the meta-analysis of molecular association studies. *Int. J. Epidemiol.* 34: 1319-1328. <u>http://dx.doi.org/10.1093/ije/dyi169</u>
- O'Donovan MC, Williams NM and Owen MJ (2003). Recent advances in the genetics of schizophrenia. *Hum. Mol. Genet.* 12: R125-R133. <u>http://dx.doi.org/10.1093/hmg/ddg302</u>

Picchioni MM and Murray RM (2007). Schizophrenia. BMJ 335: 91-95. http://dx.doi.org/10.1136/bmj.39227.616447.BE

- Ripke S, Sanders AR, Kendler KS, Levinson DF, et al.; Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (2011). Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43: 969-976. <u>http://dx.doi.org/10.1038/ng.940</u>
- Rose EJ, Morris DW, Fahey C, Cannon D, et al. (2014). The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 165B: 467-471. <u>http://dx.doi.org/10.1002/ajmg.b.32249</u>
- Saunders MA, Liang H and Li WH (2007). Human polymorphism at microRNAs and microRNA target sites. *Proc. Natl. Acad. Sci. USA* 104: 3300-3305. <u>http://dx.doi.org/10.1073/pnas.0611347104</u>
- Shi Y, Lan F, Matson C, Mulligan P, et al. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953. <u>http://dx.doi.org/10.1016/j.cell.2004.12.012</u>
- Shorter KR and Miller BH (2015). Epigenetic mechanisms in schizophrenia. Prog. Biophys. Mol. Biol. 118: 1-7. <u>http://dx.doi.org/10.1016/j.pbiomolbio.2015.04.008</u>
- Simeone JC, Ward AJ, Rotella P, Collins J, et al. (2015). An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: a systematic literature review. BMC Psychiatry 15: 193. <u>http://dx.doi.org/10.1186/ s12888-015-0578-7</u>
- Smith T, Weston C and Lieberman J (2010). Schizophrenia (maintenance treatment). Am. Fam. Physician 82: 338-339.
- Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur. J. Epidemiol.* 25: 603-605. <u>http://dx.doi.org/10.1007/s10654-010-9491-z</u>
- Strazisar M, Cammaerts S, van der Ven K, Forero DA, et al. (2015). MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. *Mol. Psychiatry* 20: 472-481. <u>http://dx.doi.org/10.1038/ mp.2014.53</u>
- Sun G, Yu RT, Evans RM and Shi Y (2007). Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc. Natl. Acad. Sci. USA 104: 15282-15287. <u>http://dx.doi.org/10.1073/pnas.0704089104</u>
- Sun G, Alzayady K, Stewart R, Ye P, et al. (2010). Histone demethylase LSD1 regulates neural stem cell proliferation. Mol. Cell. Biol. 30: 1997-2005. <u>http://dx.doi.org/10.1128/MCB.01116-09</u>
- Sun G, Ye P, Murai K, Lang MF, et al. (2011). miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. *Nat. Commun.* 2: 529. http://dx.doi.org/10.1038/ncomms1532
- Sun YJ, Yu Y, Zhu GC, Sun ZH, et al. (2015). Association between single nucleotide polymorphisms in MiR219-1 and MiR137 and susceptibility to schizophrenia in a Chinese population. FEBS Open Bio 5: 774-778. <u>http://dx.doi.org/10.1016/j.fob.2015.08.008</u>
- Suvisaari J (2010). Risk factors of schizophrenia. Duodecim 126: 869-876.
- van Erp TG, Guella I, Vawter MP, Turner J, et al. (2014). Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. *Biol. Psychiatry* 75: 398-405.<u>http://dx.doi.org/10.1016/j. biopsych.2013.06.016</u>
- van Os J and Kapur S (2009). Schizophrenia. Lancet 374: 635-645. http://dx.doi.org/10.1016/S0140-6736(09)60995-8
- Wang S, Li W, Zhang H, Wang X, et al. (2014). Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population. Int. J. Psychiatry Med. 47: 153-168. <u>http://dx.doi.org/10.2190/PM.47.2.f</u>
- Warner R (2009). Recovery from schizophrenia and the recovery model. *Curr. Opin. Psychiatry* 22: 374-380. <u>http://dx.doi.org/10.1097/YCO.0b013e32832c920b</u>
- Wright C, Turner JA, Calhoun VD and Perrone-Bizzozero N (2013). Potential Impact of miR-137 and its Targets in Schizophrenia. Front. Genet. 4: 58. <u>http://dx.doi.org/10.3389/fgene.2013.00058</u>
- Xu Y, Li F, Zhang B, Zhang K, et al. (2010). MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr. Res. 119: 219-227. <u>http://dx.doi.org/10.1016/j.schres.2010.02.1070</u>
- Yin J, Lin J, Luo X, Chen Y, et al. (2014). miR-137: a new player in schizophrenia. *Int. J. Mol. Sci.* 15: 3262-3271. <u>http://</u> dx.doi.org/10.3390/ijms15023262

11

Genetics and Molecular Research 15 (3): gmr.15038703

## M.L. Ou et al.

- Yuan J, Cheng Z, Zhang F, Zhou Z, et al. (2015). Lack of association between microRNA-137 SNP rs1625579 and schizophrenia in a replication study of Han Chinese. *Mol. Genet. Genomics* 290: 297-301. <u>http://dx.doi.org/10.1007/ s00438-014-0924-3</u>
- Zhang B, Gao CY, Zhang HB, Yang B, et al. (2015). Association of the VRK2 gene rs3732136 polymorphism with schizophrenia in a Northwest Chinese Han population. *Genet. Mol. Res.* 14: 9404-9411. <u>http://dx.doi.org/10.4238/2015.August.14.4</u>
- Zhu YS, Li YX, Qiao XM and Zhang HB (2015). Regulators of G-protein signaling 9 genetic variations in Chinese subjects with schizophrenia. *Genet. Mol. Res.* 14: 8458-8465. <u>http://dx.doi.org/10.4238/2015.July.28.13</u>

#### **Supplementary material**

Table S1. Newcastle-Ottawa scale (NOS) scores of the studies included in the meta-analysis.

Table S2. Results of sensitivity analysis.

Table S3. Effect of miR-137 rs1625579 genotypes and alleles on schizophrenia risk, according to World Health Organization region.